Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥20.47, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 44x in the Chemicals industry in China. Total returns to shareholders of 9.8% over the past three years. Annuncio • Jun 30
Shanghai Huide Science & Technology Co.,Ltd to Report First Half, 2026 Results on Aug 29, 2026 Shanghai Huide Science & Technology Co.,Ltd announced that they will report first half, 2026 results on Aug 29, 2026 New Risk • May 06
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.1% Last year net profit margin: 4.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (3.1% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Annuncio • Apr 30
Shanghai Huide Science & Technology Co.,Ltd, Annual General Meeting, May 22, 2026 Shanghai Huide Science & Technology Co.,Ltd, Annual General Meeting, May 22, 2026, at 14:30 China Standard Time. Location: No. 180, Chunhua Road, Jinshanwei Town, Jinshan District, Shanghai China Annuncio • Mar 30
Shanghai Huide Science & Technology Co.,Ltd to Report Q1, 2026 Results on Apr 30, 2026 Shanghai Huide Science & Technology Co.,Ltd announced that they will report Q1, 2026 results on Apr 30, 2026 Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥22.20, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 45x in the Chemicals industry in China. Total returns to shareholders of 14% over the past three years. New Risk • Mar 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (17% increase in shares outstanding). New Risk • Dec 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 4.0% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥28.72, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 43x in the Chemicals industry in China. Total returns to shareholders of 27% over the past three years. Annuncio • Dec 26
Shanghai Huide Science & Technology Co.,Ltd to Report Fiscal Year 2025 Results on Apr 30, 2026 Shanghai Huide Science & Technology Co.,Ltd announced that they will report fiscal year 2025 results on Apr 30, 2026 Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to CN¥27.98, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 44x in the Chemicals industry in China. Total returns to shareholders of 44% over the past three years. Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.19 (vs CN¥0.24 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.19 (down from CN¥0.24 in 3Q 2024). Revenue: CN¥673.4m (down 9.4% from 3Q 2024). Net income: CN¥26.3m (down 19% from 3Q 2024). Profit margin: 3.9% (down from 4.4% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥25.41, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 42x in the Chemicals industry in China. Total returns to shareholders of 33% over the past three years. New Risk • Oct 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Annuncio • Sep 30
Shanghai Huide Science & Technology Co.,Ltd to Report Q3, 2025 Results on Oct 29, 2025 Shanghai Huide Science & Technology Co.,Ltd announced that they will report Q3, 2025 results on Oct 29, 2025 Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥27.45, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 44x in the Chemicals industry in China. Total returns to shareholders of 9.6% over the past three years. Annuncio • Jun 30
Shanghai Huide Science & Technology Co.,Ltd to Report First Half, 2025 Results on Aug 23, 2025 Shanghai Huide Science & Technology Co.,Ltd announced that they will report first half, 2025 results on Aug 23, 2025 Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Jian Jun Jia was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Declared Dividend • May 31
Dividend increased to CN¥0.38 Dividend of CN¥0.38 is 108% higher than last year. Ex-date: 5th June 2025 Payment date: 5th June 2025 Dividend yield will be 1.8%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (40% earnings payout ratio) but not covered by cash flows (160% cash payout ratio). The dividend has increased by an average of 5.7% per year over the past 6 years. However, payments have been volatile during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.2% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (160% cash payout ratio). Share price has been volatile over the past 3 months (8.7% average weekly change). Valuation Update With 7 Day Price Move • May 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥19.46, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 38x in the Chemicals industry in China. Total loss to shareholders of 18% over the past three years. Reported Earnings • Apr 22
Full year 2024 earnings released: EPS: CN¥0.90 (vs CN¥0.46 in FY 2023) Full year 2024 results: EPS: CN¥0.90 (up from CN¥0.46 in FY 2023). Revenue: CN¥2.67b (down 1.5% from FY 2023). Net income: CN¥124.6m (up 95% from FY 2023). Profit margin: 4.7% (up from 2.4% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Annuncio • Apr 22
Shanghai Huide Science & Technology Co.,Ltd, Annual General Meeting, May 16, 2025 Shanghai Huide Science & Technology Co.,Ltd, Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: No. 180, Chunhua Road, Jinshanwei Town, Jinshan District, Shanghai China Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥15.30, the stock trades at a trailing P/E ratio of 24.7x. Average trailing P/E is 33x in the Chemicals industry in China. Total loss to shareholders of 34% over the past three years. Annuncio • Mar 28
Shanghai Huide Science & Technology Co.,Ltd to Report Q1, 2025 Results on Apr 29, 2025 Shanghai Huide Science & Technology Co.,Ltd announced that they will report Q1, 2025 results on Apr 29, 2025 Annuncio • Dec 27
Shanghai Huide Science & Technology Co.,Ltd to Report Fiscal Year 2024 Results on Apr 22, 2025 Shanghai Huide Science & Technology Co.,Ltd announced that they will report fiscal year 2024 results on Apr 22, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.16 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.24 (up from CN¥0.16 in 3Q 2023). Revenue: CN¥743.3m (down 3.6% from 3Q 2023). Net income: CN¥32.6m (up 51% from 3Q 2023). Profit margin: 4.4% (up from 2.8% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Annuncio • Sep 30
Shanghai Huide Science & Technology Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024 Shanghai Huide Science & Technology Co.,Ltd announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥15.70, the stock trades at a trailing P/E ratio of 28.5x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 8.2% over the past three years. New Risk • Aug 28
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Aug 20
Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.13 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.13 in 2Q 2023). Revenue: CN¥683.6m (up 1.9% from 2Q 2023). Net income: CN¥28.7m (up 57% from 2Q 2023). Profit margin: 4.2% (up from 2.7% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥12.48, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 27x in the Chemicals industry in China. Total loss to shareholders of 27% over the past three years. Annuncio • Jun 28
Shanghai Huide Science & Technology Co.,Ltd to Report First Half, 2024 Results on Aug 20, 2024 Shanghai Huide Science & Technology Co.,Ltd announced that they will report first half, 2024 results on Aug 20, 2024 New Risk • May 17
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Buy Or Sell Opportunity • May 07
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 47% to CN¥16.21. The fair value is estimated to be CN¥13.48, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.7% over the last 3 years. Earnings per share has declined by 32%. Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.09 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.11 (up from CN¥0.09 in 1Q 2023). Revenue: CN¥670.5m (up 14% from 1Q 2023). Net income: CN¥14.7m (up 17% from 1Q 2023). Profit margin: 2.2% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Annuncio • Apr 21
Shanghai Huide Science & Technology Co.,Ltd, Annual General Meeting, May 13, 2024 Shanghai Huide Science & Technology Co.,Ltd, Annual General Meeting, May 13, 2024, at 13:00 China Standard Time. Reported Earnings • Apr 20
Full year 2023 earnings released: EPS: CN¥0.46 (vs CN¥0.50 in FY 2022) Full year 2023 results: EPS: CN¥0.46. Revenue: CN¥2.71b (down 10% from FY 2022). Net income: CN¥63.9m (up 3.4% from FY 2022). Profit margin: 2.4% (up from 2.0% in FY 2022). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥12.89, the stock trades at a trailing P/E ratio of 35.4x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 27% over the past three years. Annuncio • Mar 29
Shanghai Huide Science & Technology Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024 Shanghai Huide Science & Technology Co.,Ltd announced that they will report Q1, 2024 results on Apr 30, 2024 New Risk • Mar 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (1.9% net profit margin). Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to CN¥11.81, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 24x in the Chemicals industry in China. Total loss to shareholders of 25% over the past three years. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥18.00, the stock trades at a trailing P/E ratio of 48.6x. Average trailing P/E is 32x in the Chemicals industry in China. Total returns to shareholders of 10% over the past three years. Annuncio • Dec 29
Shanghai Huide Science & Technology Co.,Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024 Shanghai Huide Science & Technology Co.,Ltd announced that they will report fiscal year 2023 results on Apr 20, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.15 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.16 (up from CN¥0.15 in 3Q 2022). Revenue: CN¥770.8m (up 4.5% from 3Q 2022). Net income: CN¥21.6m (up 4.3% from 3Q 2022). Profit margin: 2.8% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.25 in 2Q 2022). Revenue: CN¥671.0m (down 17% from 2Q 2022). Net income: CN¥18.3m (down 16% from 2Q 2022). Profit margin: 2.7% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Annuncio • Jun 28
Shanghai Huide Science & Technology Co.,Ltd to Report First Half, 2023 Results on Aug 29, 2023 Shanghai Huide Science & Technology Co.,Ltd announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • Apr 24
Full year 2022 earnings released: EPS: CN¥0.50 (vs CN¥0.85 in FY 2021) Full year 2022 results: EPS: CN¥0.50 (down from CN¥0.85 in FY 2021). Revenue: CN¥3.02b (down 5.5% from FY 2021). Net income: CN¥61.8m (down 48% from FY 2021). Profit margin: 2.0% (down from 3.7% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.26 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.15 (down from CN¥0.26 in 3Q 2021). Revenue: CN¥737.4m (down 23% from 3Q 2021). Net income: CN¥20.7m (down 40% from 3Q 2021). Profit margin: 2.8% (down from 3.6% in 3Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year. Reported Earnings • Aug 20
Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.21 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.25. Revenue: CN¥807.2m (up 5.2% from 2Q 2021). Net income: CN¥21.8m (down 29% from 2Q 2021). Profit margin: 2.7% (down from 4.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥28.00, the stock trades at a trailing P/E ratio of 34.2x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 42% over the past three years. Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥28.72, the stock trades at a trailing P/E ratio of 35x. Average trailing P/E is 28x in the Chemicals industry in China. Total returns to shareholders of 38% over the past three years. Valuation Update With 7 Day Price Move • May 23
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥31.77, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 25x in the Chemicals industry in China. Total returns to shareholders of 24% over the past three years. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.24 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.20 (down from CN¥0.24 in 1Q 2021). Revenue: CN¥820.9m (up 52% from 1Q 2021). Net income: CN¥21.0m (down 16% from 1Q 2021). Profit margin: 2.6% (down from 4.7% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year. Reported Earnings • Apr 21
Full year 2021 earnings released: EPS: CN¥1.10 (vs CN¥1.16 in FY 2020) Full year 2021 results: EPS: CN¥1.10 (down from CN¥1.16 in FY 2020). Revenue: CN¥3.19b (up 113% from FY 2020). Net income: CN¥117.8m (down 5.2% from FY 2020). Profit margin: 3.7% (down from 8.3% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 3% per year. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥40.76, the stock trades at a trailing P/E ratio of 30.1x. Average trailing P/E is 33x in the Chemicals industry in China. Total returns to shareholders of 46% over the past three years. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥58.36, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 110% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥50.04, the stock trades at a trailing P/E ratio of 37x. Average trailing P/E is 35x in the Chemicals industry in China. Total returns to shareholders of 66% over the past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.33 (vs CN¥0.27 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥961.3m (up 107% from 3Q 2020). Net income: CN¥34.7m (up 21% from 3Q 2020). Profit margin: 3.6% (down from 6.2% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 9% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 20
Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.22 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥767.7m (up 187% from 2Q 2020). Net income: CN¥30.7m (up 28% from 2Q 2020). Profit margin: 4.0% (down from 9.0% in 2Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Apr 21
Full year 2020 earnings released: EPS CN¥1.16 (vs CN¥1.24 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: CN¥1.50b (up 4.0% from FY 2019). Net income: CN¥124.2m (down 6.0% from FY 2019). Profit margin: 8.3% (down from 9.2% in FY 2019). The decrease in margin was driven by higher expenses. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥20.50 The company is down 23% from its price of CN¥26.47 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥22.76 The company is down 10.0% from its price of CN¥25.26 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. Is New 90 Day High Low • Dec 10
New 90-day low: CN¥24.97 The company is down 3.0% from its price of CN¥25.63 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 10.0% over the same period. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥100.7m, down 20% from the prior year. Total revenue was CN¥1.32b over the last 12 months, down 5.1% from the prior year. Is New 90 Day High Low • Sep 28
New 90-day low: CN¥24.98 The company is down 4.0% from its price of CN¥26.00 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period. Annuncio • Jul 09
Shanghai Huide Science & Technology Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020 Shanghai Huide Science & Technology Co.,Ltd announced that they will report first half, 2020 results on Aug 21, 2020